{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "31479044", "DateCompleted": {"Year": "2021", "Month": "04", "Day": "28"}, "DateRevised": {"Year": "2021", "Month": "04", "Day": "28"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.1097/FTD.0000000000000698"], "Journal": {"ISSN": "1536-3694", "JournalIssue": {"Volume": "42", "Issue": "1", "PubDate": {"Year": "2020", "Month": "Feb"}}, "Title": "Therapeutic drug monitoring", "ISOAbbreviation": "Ther Drug Monit"}, "ArticleTitle": "Using Therapeutic Drug Monitoring and Pharmacovigilance to Overcome Some of the Challenges of Developing Medicinal Cannabis from Botanical Origins.", "Pagination": {"StartPage": "98", "EndPage": "101", "MedlinePgn": "98-101"}, "Abstract": {"AbstractText": ["Plants belonging to the genus Cannabis have been domesticated and used by humans for millennia. Thought to have originated from central Asia, cannabis has been harnessed for its nutritional, therapeutic, and psychoactive properties, and as a source of fiber (Office of Medicinal Cannabis. Analytical Monograph Cannabis Flos. Den Haag, The Netherlands: Office of Medicinal Cannabis; 2014). Human use of cannabis is not novel; however, its medicalization offers a new pharmacotherapeutic frontier.", "The authors recently reported a systematic review of the contaminants of cannabis (National Academies of Sciences Engineering, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC; 2017). This article draws on the research limitations identified by that review and examines a collection of the relevant literature to provide an appreciation of the current evidence base.", "The review explores the current status of cannabis in medical use, the drug development aspects that apply when taking a plant through to pill development, and the roles that therapeutic drug monitoring and pharmacovigilance have to guide practice until the drug development information on medicinal cannabis preparations is complete.", "A surge of public and clinical interest in the possible therapeutic applications of constituent cannabinoids has potentiated global legislative and policy reform. However, our understanding of its properties, optimized use, and harmful effects remains incomplete (Therapeutic Goods Administration. Guidance for the use of medicinal cannabis in Australia In: Department of Health Department, editor. Woden ACT Australian Government 2017; Dryburgh LM, Bolan NS, Grof CP, Galettis P, Schneider J, Lucas CJ, et al. Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects. Brit J Clin Pharm. 2018;84(11):2468-2476). In particular, a comprehensive appreciation of its toxicity profile is lacking."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicine, Faculty of Health and Medicine, The University of Newcastle Australia, Newcastle, Australia."}, {"Identifier": [], "Affiliation": "Hunter Medical Research Institute; and."}], "LastName": "Dryburgh", "ForeName": "Laura M", "Initials": "LM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicine, Faculty of Health and Medicine, The University of Newcastle Australia, Newcastle, Australia."}, {"Identifier": [], "Affiliation": "Hunter Medical Research Institute; and."}, {"Identifier": [], "Affiliation": "The Australian Centre for Cannabinoid Clinical and Research Excellence."}], "LastName": "Martin", "ForeName": "Jennifer H", "Initials": "JH"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Ther Drug Monit", "NlmUniqueID": "7909660", "ISSNLinking": "0163-4356"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Cannabinoids"}, {"RegistryNumber": "0", "NameOfSubstance": "Medical Marijuana"}], "MeshHeadingList": [{"QualifierName": ["chemistry", "pharmacokinetics", "therapeutic use"], "DescriptorName": "Cannabinoids"}, {"QualifierName": ["chemistry"], "DescriptorName": "Cannabis"}, {"QualifierName": [], "DescriptorName": "Dose-Response Relationship, Drug"}, {"QualifierName": [], "DescriptorName": "Drug Administration Routes"}, {"QualifierName": [], "DescriptorName": "Drug Contamination"}, {"QualifierName": [], "DescriptorName": "Drug Development"}, {"QualifierName": ["methods"], "DescriptorName": "Drug Monitoring"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["administration & dosage", "adverse effects", "pharmacokinetics", "therapeutic use"], "DescriptorName": "Medical Marijuana"}, {"QualifierName": [], "DescriptorName": "Pharmacovigilance"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Madras B. Update of cannabis and its medical use. In: Report to the WHO Expert Committee on Drug Dependence. Geneva, Switzerland: World Health Organisation; 2015."}, {"Citation": "National Academies of Sciences Engineering and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: National Academies Press; 2017."}, {"Citation": "Radwan M, Wanas A, Chandra S, et al. Natural Cannabinoids of Cannabis and Methods of Analysis. In: Chandra S, Lata H, Elsohly M, editors. Cham, Switzerland: Springer; 2017."}, {"Citation": "Murnion B. Medicinal cannabis. Aust Prescriber. 2015;38:212\u2013215."}, {"Citation": "European Monitoring Centre for Drugs and Drug Addiction. Medical Use of Cannabis and Cannabinoids. Questions and Answers for Policymaking. Luxembourg: Publications Office of the European Union: European Monitoring Centre for Drugs and Drug Addiction; 2018."}, {"Citation": "United Nations. Single Convention on Narcotic Drugs. New York, NY: United Nations; 1961."}, {"Citation": "Therapeutic Goods Order Number 93\u2014Standard for Medicinal Cannabis. Therapeutic Goods Act 1989. Canberra, Australia: Australian Government; 2017."}, {"Citation": "Office of Medicinal Cannabis. Analytical Monograph Cannabis Flos. Den Haag, the Netherlands: Office of Medicinal Cannabis; 2014."}, {"Citation": "MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Int Med. 2018;49:12\u201319."}, {"Citation": "Therapeutic Goods Administration. Guidance for the Use of Medicinal Cannabis in Australia. In: Department of Health, ed. Woden ACT Australian Government Canberra, Australia: Australian Government; 2017."}, {"Citation": "Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic-review and meta-analysis. JAMA. 2015;313:2456\u20132473."}, {"Citation": "Schiff P. Opium and its alkaloids. Am J Pharm Ed. 2002;66:188\u2013196."}, {"Citation": "Beckett A, Casy A. Synthetic analgesics: stereochemical considerations. J Pharm Pharmacol. 1954;6:986\u20131001."}, {"Citation": "Martin W, Eades C, Thompson J, et al. The effects of morphine\u2014and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther. 1976:197:517\u2013532."}, {"Citation": "Hughes J, Smith T, Kosterlitz H, et al. Identification of two related peptides from the brain with potent opiate agonist activity. Nature. 1975;258:577\u2013580."}, {"Citation": "Lord J, Waterfield A, Hughes J, et al. Endogenous opioid peptides: multiple agonists and receptors. Nature. 1977;267:495\u2013499."}, {"Citation": "Corbett A, Henderson G, McKnight A, et al. 75 years of opioid research: the exciting but vain quest for the Holy Grail. Br J Pharmacol. 2009;147:S153\u2013S162."}, {"Citation": "National Medicines Policy. In: Department of Health and Ageing, editor. Canberra, Australia: Australian Government; 2000."}, {"Citation": "Narcotic Drugs Amendment Act 2016 (Cth), Stat.C2016A00012. Canberra, Australia: Australian Government; 2016."}, {"Citation": "Clinical Guidance: For the Use of Medicinal Cannabis Products in Queensland. In: Department of Health Office of Medicinal Cannabis, ed. Queensland Health 2018. Brisbane, Australia. Available at: https://www.health.qld.gov.au/public-health/topics/medicinal-cannabis/prescribing."}, {"Citation": "Barco S, Fucile C, Manfredini L, et al. A UHPLC\u2013MS/MS method for the quantification of \u03949-tetrahydrocannabinol and cannabidiol in decoctions and in plasma samples for therapeutic monitoring of medical cannabis. Bioanalysis. 2018;10:2003\u20132014."}, {"Citation": "Camargo SPS, Queiroz RHC, Mafara WR, et al. Developement and validation of a liquid-liquid extraction and gas chromatography/mass spectrometry methodology for cannabidiol analysis in human plasma. Curr Pharm Anal. 2011;7:228\u2013234."}, {"Citation": "Mercollini L, Musenga A, Comin I, et al. Determination of plasma and urine levels of DELTA9-tetrahydrocannabinol and its main metabolite by liquid chromatography after solid-phase extraction. J Pharm Biomed Anal. 2008;47:156\u2013163."}, {"Citation": "Ferreir\u00f3s N. Recent advances in LC-MS/MS analysis of Delta(9)-tetrahydrocannabinol and its metabolites in biological matrices. Bioanalysis. 2013;5:2713\u20132731."}, {"Citation": "Solowij N, Broyd SJ, van Hell HH, Hazekamp A. A protocol for the delivery of cannabidiol (CBD) and combined CBD and \u22069-tetrahydrocannabinol (THC) by vaporisation. BMC Pharmacol Toxicol. 2014;15:58."}, {"Citation": "Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4:1770\u20131804."}, {"Citation": "Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42:327\u2013360."}, {"Citation": "Louizos C, Y\u00e1\u00f1ez JA, Forrest ML, et al. Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships. J Pharm Pharm Sci. 2014;17:34\u201391."}, {"Citation": "Cocchetto DM, Owens M, Perez-Reyes M, et al. Relationship between plasma delta-9-tetrahydrocannabinol concentration and pharmacologic effects in man. Psychopharmacology. 1981;75:158\u2013164."}, {"Citation": "Shwiope DM, Bosker WM, Ramaekers JG, et al. Psychomotor performance, subjective and physiological effects and whole blood \u03949-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis. J Anal Toxicol. 2012;36:405\u2013412."}, {"Citation": "Wilsey BL, Deutsch R, Samara E, et al. A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis. J Pain Res. 2016;9:587\u2013598."}, {"Citation": "Dryburgh LM, Bolan NS, Grof CP, et al. Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects. Br J Clin Pharm. 2018;84:2468\u20132476."}, {"Citation": "Koldony A, Courtwright DT, Hwang CS, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Publ Health. 2015;36:559\u2013574."}, {"Citation": "Becker WC, Fiellin DA. Limited evidence, faulty reasoning, and potential for a global opioid crisis. BMJ. 2017;5:358."}]}], "History": [{"Year": "2019", "Month": "9", "Day": "4", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "4", "Day": "29", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "9", "Day": "4", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["31479044", "10.1097/FTD.0000000000000698", "00007691-202002000-00011"]}}]}